News and Trends 9 May 2017 AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal As part of the deal with Sanofi, Exscientia will tackle the discovery and design of new bispecific drugs using artificial intelligence algorithms. Exscientia, based in Scotland, is a company that uses artificial intelligence (AI) to develop new drugs faster. Its edge-cutting technology has caught the attention of Sanofi, which is offering Exscientia research funding and […] May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 May 2017 British Biotech Startup Partners with Takeda to Advance its T Cell Platform GammaDelta Therapeutics and Takeda have formed a strategic collaboration to develop a novel T cell platform, which is based on gamma delta (γδ) T cells. Based in London, GammaDelta Therapeutics builds on the work of Adrian Hayday and Oliver Nussbaumer of Kings College London and The Francis Crick Institute. Backed by the huge British VC […] May 9, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 9 May 2017 Scottish Shark Antibodies have caught Amgen’s Eye Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest naturally-occurring antibody binding domains. “They are remarkably stable,” Caroline Barelle told me this morning at BioTrinity in London. “They can survive extreme pH and temperatures […] May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2017 Hypermutation could be the Key to Biofuels – and Antibiotic Resistance Instead of taking a spa vacation, stressed out bacteria start mutating their DNA fast. This nearly suicidal behavior can yield a lucky survivor in nature. For us, it could mean new strategies for biofuel production and fighting antibiotic resistance, researchers say. Researchers from the Centre of Microbial and Plant Genetics at KU Leuven, in Belgium, are shining […] May 9, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
In Depth 9 May 2017 Rise of the Superbugs: How is Biotech Fighting Antibiotic Resistance? Fewer antibiotics are produced as development costs rise. We reached out to a few companies addressing the serious issue of antibiotic resistance. Antibiotic resistance is one of the greatest threats to our societies and health systems, and the number of antibiotic-resistant bacteria is growing at a disquieting rate. The estimated number of people killed by […] May 9, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 The EU Approves New Treatment for a Rare Pediatric Cancer Update (08/05/2017): The European Commission has granted marketing authorization to Apeiron Biologic’s APN311 in the rare pediatric cancer neuroblastoma. Originally published on 27/03/2017 Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high-risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches to treat cancer. […] May 8, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis Teva and Active Biotech have failed Phase III with their Multiple Sclerosis drug laquinimod to treat the relapsing-remitting form of the disease. Teva and Active Biotech have faced another setback with their long-expected successor to Teva’s Copaxone, laquinimod, for the treatment of Multiple Sclerosis (MS). The drug failed to meet the primary endpoint, trying to improve the […] May 8, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 French Researchers Discover a Target to Prevent Zika Birth Defects Researchers from the Institut Pasteur and the Inserm have identified a protein target that, when overexpressed, can block Zika infections. The recent Zika epidemics in the Pacific and South America has led the World Health Organization (WHO) to declare a state of global emergency. One of the biggest concerns at the moment is that the […] May 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 Immunocore Boosts its Collaboration with GSK with new Lead Compound Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by […] May 8, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 Top 5 Mistakes that Will Doom a CRO-Supplier Partnership Before it Starts A healthy relationship between a trial sponsor and the CRO or supplier can be the key to success – here is a list of how to address the biggest challenges. By 2020, 72% of clinical trials are projected to be outsourced to contract research organizations (CROs), compared to just 23% in 2012. The main reason […] May 8, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 8 May 2017 Meet the co-developer of the first commercial mAb and gene therapy Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the first commercial monoclonal antibody, Remicade, and the first market-approved gene therapy, Glybera. I was curious to know what he did to achieve such an impressive track record. Sander van Deventer was trained as an internist […] May 8, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
More News! 6 May 2017 Color Patterns in the Clothes of the Future will be Made by Bacteria Natsai Audrey Chieza is an artist and researcher exploring the integration of life into the manufacturing of the materials of the future. Natsai Audrey Chieza wants to break with the current paradigm of fashion design and textile production with the help of microbiology. Her research focuses on developing bacterial biopigments for textiles to replace the […] May 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email